Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation
The collaboration is exploratory, with agreed outcome measures planned to assess whether approaches could extend across diseases and geographies.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oracle (ORCL) announced a non-binding agreement with AstraZeneca to explore AI and real-world data applications in clinical research and care. The companies plan to combine AstraZeneca's scientific expertise with Oracle's data, cloud, AI and clinical workflow capabilities to explore earlier identification of eligible trial patients and faster evidence generation.
Potential disease areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases. The companies plan shared governance, reusable technical components and agreed outcome measures to assess results and determine whether successful approaches could extend across disease areas and geographies.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.AstraZeneca collaboration plans to combine scientific expertise with Oracle's technology to explore clinical research and care applications.
- Minor point. Forward-looking: it has not happened yet and may not happen.Shared governance and outcome measures are planned to assess results and potential expansion across diseases and geographies.
Negative
- Minor pointNon-binding agreement establishes an exploratory collaboration rather than a binding commitment.
Key Terms
real-world data medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Collaboration to connect AstraZeneca's scientific and therapeutic expertise with Oracle's real-world data, cloud, AI, and clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to help improve patient care
Through a non-binding agreement, the companies plan to explore selected use cases that could improve clinical-trial efficiency and success by leveraging modern applications and AI to help care teams identify eligible patients earlier and easier, resulting in greater access to clinical trials for patients in need and helping to overcome one of the largest obstacles in clinical trials - patient recruitment. Initial disease areas to be explored could include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunology; and rare diseases.
Pascal Soriot, Chief Executive Officer, AstraZeneca said: "This unique collaboration brings leaders in healthcare and AI together at a global scale to accelerate the journey from the discovery of medicine to patient care. Combining AstraZeneca's world class science with Oracle's deep data and technology expertise, we can help clinicians identify patients sooner, optimize clinical trials, and generate evidence continuously across the lifecycle of a medicine."
"Some of the most important opportunities for AI are in healthcare, where better use of data can help turn scientific innovation into better outcomes for patients," noted Mike Sicilia, chief executive officer, Oracle. "By bringing AstraZeneca's scientific expertise together with Oracle's data, cloud, AI, and healthcare capabilities, we have an opportunity to help accelerate research, connect more patients to clinical trials, and ultimately bring relevant insights into care faster."
Connecting Research and Care
Anne-Claire Gerbaldi, Chief Digital, Data and AI Officer, AstraZeneca, added: "Too many patients are diagnosed late or face a long journey to get the care they need. To build the next decade of medicine, we aim to harness AI to connect learnings across science, clinical trials, and everyday care, generating insights that continuously strengthen research, accelerate innovation, and enhance patient outcomes. Bringing together the unique capabilities of Oracle and AstraZeneca, we believe we can support smarter clinical trials, strengthen safety monitoring, and help ensure patients are diagnosed sooner and receive the right care."
Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences, said: "Healthcare progress depends on shortening the distance between scientific insight and the decisions clinicians make every day. AstraZeneca brings deep scientific and therapeutic expertise, and Oracle will deliver the secure data, cloud, AI, and clinical workflow capabilities. This collaboration has the potential to help health systems identify eligible patients sooner, broaden access to clinical trials, and generate evidence that supports the next decision, all under the governance of the health systems delivering care."
AstraZeneca and Oracle intend to explore a continuous learning model in which insights from clinical research and routine care help inform future study design, safety monitoring, and patient care. The companies plan to establish shared governance, reusable technical components, and agreed outcome measures to assess results and determine whether successful approaches could extend across disease areas and geographies.
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit www.oracle.com.
Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company - ushering in the new era of cloud computing.
View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-astrazeneca-partner-to-advance-ai-enabled-healthcare-innovation-302913441.html
SOURCE Oracle
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What will Oracle and AstraZeneca explore under their AI healthcare agreement?
Oracle and AstraZeneca plan to explore AI and real-world data applications that help identify eligible clinical-trial patients, accelerate evidence generation and bring research insights into everyday care. The agreement is non-binding.
How would Oracle and AstraZeneca connect clinical research with routine care?
The companies intend to explore a continuous learning model in which insights from research and routine care inform future study design, safety monitoring and patient care. Oracle describes the potential work as operating under the governance of the health systems delivering care.